0

Association of HLA Antigens, Toxic Reactions and Therapeutic Response to Auranofin and Aurothioglucose in Patients With Rheumatoid Arthritis

P L van Riel, P Reekers, L B van de Putte, F W Gribnau

Tissue Antigens. 1983 Sep;22(3):194-9.

PMID: 6415865

Abstract:

To investigate the possible relation between HLA antigens and either favourable clinical response or toxic reaction to two different gold compounds, aurothioglucose and auranofin, a new orally absorbable gold compound, we studied 50 patients with rheumatoid arthritis prospectively. Of the 25 aurothioglucose-treated patients, response to treatment could not be evaluated in four patients because of early toxicity. Nine patients showed an excellent response, while 12 were moderate or non-responders. Four of the 9 excellent responders were HLA-DR3 positive, but none of the 12 moderate or non-responders possessed this antigen (P less than 0.025). In accordance with previous reports HLA-DR3 was found more frequently in patients developing toxicity on aurothioglucose than in those who did not (RR = 5.6). No association was found between HLA antigens and favourable clinical response in 25 auranofin-treated patients. Two of them showed a severe adverse reaction, neither of them being DR3-positive. HLA-DR3 positivity is associated not only with drug toxicity, but also with excellent respondership to aurothioglucose treatment.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP12192573 Aurothioglucose Aurothioglucose 12192-57-3 Price
qrcode